Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of oral ozanimod (RPC1063) for moderate to severe ulcerative colitis
2015-001600-64Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in autoimmune colitis, sponsored by Celgene Corporation. Primary endpoints: Efficacy endpoints (descriptive) and Safety endpoints (descriptive). Started Jul 2015; status: active.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-001600-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001600-64.